(Q43255238)
Statements
1 reference
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression (English)
1 reference
Carlo Aul
1 reference
Aristoteles Giagounidis
1 reference
Gudrun Göhring
1 reference
Guntram Büsche
1 reference
Hans Heinrich Kreipe
1 reference
Martin Zimmermann
1 reference
Eva Hellström-Lindberg
1 reference
Brigitte Schlegelberger
1 reference
24 October 2009
1 reference
1 reference
89
1 reference
4
1 reference
365-374
1 reference
Identifiers
1 reference
1 reference